STEP-3 Trial: A Plain-English Overview of What It Established

At a glance

| Parameter | Detail | |-----------|--------| | Trial name | STEP-3 (Semaglutide Treatment Effect in People with Obesity, trial 3) | | N | 611 randomized (407 semaglutide, 204 placebo) | | Population | Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity, without diabetes | | Intervention | Subcutaneous semaglutide 2.4 mg once weekly + intensive behavioral therapy (IBT) | | Comparator | Matched placebo injection + identical IBT program | | Duration | 68 weeks (16-week dose escalation, then 52 weeks at full dose) | | Primary endpoint | Percent change in body weight from baseline to week 68 | | Key result | -16.0% semaglutide+IBT vs -5.7% placebo+IBT (estimated treatment difference: -10.3 percentage points; p <0.001) | | Registration | NCT03611582 | | Published | February 2021, JAMA |

The Question STEP-3 Was Designed to Answer

Every obesity guideline recommends lifestyle modification as first-line therapy. The question that mattered clinically was whether adding a GLP-1 receptor agonist to a rigorous behavioral program would produce meaningfully greater weight loss than the behavioral program alone. Earlier STEP trials (STEP-1 and STEP-2) tested semaglutide against diet-and-exercise counseling, but counseling in those studies was relatively brief. STEP-3 deliberately paired both arms with an intensive 30-session behavioral intervention and an 8-week low-calorie diet run-in, raising the bar for the comparator. If semaglutide still separated from placebo under these conditions, clinicians could feel confident the drug adds pharmacological benefit independent of behavioral effort.

Who Was Enrolled (and Who Was Excluded)

Participants were 18 years or older, had a BMI ≥30 kg/m² (or ≥27 with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea), and did not have type 2 diabetes. Prior bariatric surgery was exclusionary, as were recent cardiovascular events. The population was predominantly White (78%) and female (78%), reflecting recruitment patterns common in U.S. obesity trials. Mean baseline weight was approximately 106 kg and mean BMI was 38 kg/m².

Of 611 participants randomized, 567 (92.8%) completed the trial and had at least one post-baseline assessment, which was a strong retention rate for a 68-week study.

The Intervention in Detail

Drug component

Semaglutide was escalated over 16 weeks following a fixed schedule: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. This is the same escalation used in the Wegovy prescribing information. Placebo injections were volume-matched.

Behavioral component

Both arms received identical IBT consisting of 30 individual counseling sessions over 68 weeks. Sessions were most frequent in the first 8 weeks, during which participants followed a low-calorie diet (1,000 to 1,200 kcal/day using meal replacements). After week 8, the meal-replacement phase ended and participants transitioned to a conventional hypocaloric diet. Physical activity targets increased progressively to 200 minutes per week. The IBT structure drew from the Diabetes Prevention Program model, considered a gold standard for lifestyle-based weight management.

This design is critical context. The comparator arm was not a "do nothing" group. Placebo-plus-IBT participants had professional dietitian support, structured calorie goals, and exercise coaching for over a year.

What Was Measured

The co-primary endpoints were:

1. Percent change in body weight from baseline to week 68
2. Proportion of participants achieving ≥5% body weight loss at week 68

Secondary endpoints included proportions achieving ≥10% and ≥15% weight loss, changes in waist circumference, systolic blood pressure, lipid panels, C-reactive protein, and patient-reported physical functioning (SF-36).

The trial used an intention-to-treat estimand (treatment policy estimand), meaning all randomized participants were included in the primary analysis regardless of adherence or early discontinuation. A secondary "trial product estimand" analyzed results assuming on-treatment adherence.

Results: The Numbers That Matter

Weight loss

| Outcome | Semaglutide + IBT | Placebo + IBT | Difference (95% CI) | |---------|-------------------|---------------|---------------------| | Mean % weight change at wk 68 | -16.0% | -5.7% | -10.3 (-12.0 to -8.6) | | ≥5% weight loss | 86.6% | 47.6% | p <0.001 | | ≥10% weight loss | 75.3% | 27.0% | p <0.001 | | ≥15% weight loss | 55.8% | 13.2% | p <0.001 | | ≥20% weight loss | 36.7% | 3.7% | p <0.001 |

More than one in three semaglutide-treated participants lost 20% or more of their body weight. In the placebo arm, despite an intensive program, only about 1 in 27 reached that threshold.

Absolute weight loss

Mean absolute change: approximately -16.8 kg in the semaglutide group vs -6.2 kg with placebo. The average participant on semaglutide lost about 37 pounds.

Cardiometabolic markers

Waist circumference decreased by 14.6 cm (semaglutide) vs 6.3 cm (placebo). Systolic blood pressure fell by 5.6 mmHg vs 2.2 mmHg. CRP, a marker of systemic inflammation, decreased substantially more in the semaglutide arm. Lipid improvements were modest but consistent.

Patient-reported outcomes

Physical functioning scores on the SF-36 improved significantly more with semaglutide (mean improvement 3.0 points vs 1.5 points), though both groups showed gains.

Safety and Tolerability

Gastrointestinal adverse events were the most common reason for discontinuation. Nausea occurred in 57.1% of semaglutide-treated participants versus 28.4% of placebo participants. Diarrhea (35.9% vs 21.6%) and constipation (29.5% vs 14.2%) were also more frequent. Most GI events were mild-to-moderate and occurred during dose escalation, declining after week 20.

Serious adverse events occurred in 9.1% (semaglutide) vs 2.9% (placebo). Two participants in the semaglutide arm developed acute pancreatitis, consistent with the known class signal. Gallbladder-related events (cholelithiasis or cholecystitis) occurred in 2.7% of the semaglutide group, which aligns with the increased gallstone risk seen during rapid weight loss generally.

No new safety signals emerged beyond what was already documented for semaglutide in STEP-1 and known from the drug's earlier diabetes indications.

Limitations the Authors Acknowledged

The investigators explicitly noted several caveats in the published paper:

• Short duration relative to a chronic disease. Obesity is lifelong; the trial lasted 68 weeks with no post-treatment follow-up built into the primary analysis.
• Limited diversity. The cohort was 78% White and 78% female. Generalizability to men, Black, Hispanic, and Asian populations is uncertain.
• No direct comparison to semaglutide without IBT. The trial cannot tell us exactly how much the behavioral program added vs. drug alone (STEP-1 provides an indirect comparison: 14.9% weight loss with less intensive counseling).
• Placebo arm received the same IBT. While this strengthens internal validity, it makes the comparator stronger than what most patients receive in routine clinical care, potentially underestimating real-world additive benefit.
• Industry sponsorship. Novo Nordisk funded the trial and participated in study design and data analysis.

Putting STEP-3 in Context

Comparing STEP-3 results to STEP-1 (semaglutide with standard counseling) reveals something interesting. STEP-1 produced 14.9% weight loss; STEP-3 produced 16.0%. The difference (roughly 1 percentage point) suggests intensive behavioral therapy adds a modest increment on top of semaglutide's pharmacological effect. The larger story is that the drug's contribution dwarfs what IBT adds to it, not the reverse.

The 2022 American Gastroenterological Association guideline on pharmacological management of obesity cited STEP-3 as evidence supporting combination pharmacotherapy-plus-lifestyle approaches. The Endocrine Society's 2024 guideline similarly references the STEP program as the evidence base for semaglutide's approval at 2.4 mg for chronic weight management.

What This Means for Clinical Practice Today

STEP-3 established three practical points:

1. Semaglutide works even when the comparator is aggressive. Clinicians sometimes worry that weight-loss drugs only outperform inadequate lifestyle programs. STEP-3 demonstrated a 10-percentage-point separation over a structured, professionally supervised behavioral intervention.

2. IBT adds something, but not as much as the drug. Cross-trial comparison suggests the combination yields about 1 extra percentage point over semaglutide alone. For payers debating whether to require formal behavioral programs before approving medication, the incremental benefit is real but small.

3. Early low-calorie diets paired with GLP-1 escalation are feasible. The 8-week meal-replacement induction did not produce excess adverse events and may have accelerated early results, which could reinforce patient motivation during the slow escalation period.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. PubMed
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
3. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. June 2021. FDA Label
4. Amaro A, Sugimoto D, Wharton S, et al. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134(sup1):5-17. PubMed
5. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203. PubMed
6. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8). JAMA. 2022;327(2):138-150. PubMed